Therapy goals. Just about every GLP-one agonist has distinct accepted works by using and prospective Rewards to help you satisfy your treatment method objectives.In Oct 2024, Novo Nordisk revealed a examine on scientific journal Nature a couple of novel glucose-delicate insulin NNC2215 that could reduce the risk of hypoglycemia in animal models.[67